

# Novavax to Participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference

November 23, 2021

GAITHERSBURG, Md., Nov. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Evercore ISI's 4<sup>th</sup> Annual HealthCONx Virtual Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

## Conference Details:

### *Fireside Chat*

Date: Thursday, December 2, 2021  
Time: 9:15 – 9:35 a.m. Eastern Time (ET)  
Moderator: Josh Schimmer  
Novavax participants: Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer

### *Conference*

Event: Investor meetings  
Date: Thursday, December 2, 2021

A replay of the recorded fireside session will be available through the events page of the Company's website at [ir.novavax.com](https://ir.novavax.com) for 90 days.

## About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, received Emergency Use Authorization in Indonesia and the Philippines and has been submitted for regulatory authorization in multiple markets globally. NanoFlu™, the company's quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Novavax is currently evaluating a COVID-NanoFlu™ combination vaccine in a Phase 1/2 clinical trial, which combines the company's NVX-CoV2373 and NanoFlu™ vaccine candidates. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit [www.novavax.com](https://www.novavax.com) and connect with us on [Twitter](#) and [LinkedIn](#).

## Contacts:

### Investors

Novavax, Inc.  
Erika Schultz | 240-268-2022  
[ir@novavax.com](mailto:ir@novavax.com)

Solebury Trout  
Alexandra Roy | 617-221-9197  
[aroy@soleburytrout.com](mailto:aroy@soleburytrout.com)

### Media

Alison Chartan | 240-720-7804  
Laura Keenan Lindsey | 202-709-7521  
[media@novavax.com](mailto:media@novavax.com)

SOURCE Novavax, Inc.

Image not found or type unknown